Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole versus tamoxifen adjuvant therapy trial in postmenopausal women with hormone receptor-positive early breast cancer
ACTRN12607000012471Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 1999
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of letrozole and tamoxifen in breast cancer (4 arms), sponsored by Novartis. Primary endpoint: Disease-free survival. Started Apr 1999; status: completed.
02
Drugs
letrozoletamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000012471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000012471.